Email this article Chronic obstructive pulmonary disease and arterial hypertension: methaphysics and dialectic
- Authors: Li V.V1, Zadionchenko V.S1, Adasheva T.V1, Pavlov S.V1, Shakhrai N.B1
-
Affiliations:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation
- Issue: Vol 4, No 1 (2013)
- Pages: 5-10
- Section: Articles
- URL: https://journal-vniispk.ru/2221-7185/article/view/44977
- DOI: https://doi.org/10.26442/CS44977
- ID: 44977
Cite item
Full Text
Abstract
The paper provides a review of prevalence and outcomes of cardiovascular comorbidities in patients with chronic obstructive pulmonary disease (COPD). From a clinical and patient-centered perspective, a COPD phenotype should be able to classify patients into distinct subgroups that provide prognostic information and allow to better determine appropriate therapy that alters clinically meaningful outcomes. It is hypothesized that both COPD and artherial hypertension (AH) have common pathway linking these comorbidities and explaining why they significantly complicate the management and influence the prognosis of patients with COPD and AH. Further studies will be required to explore this hypothesis and understand the relationship between COPD and AH.
Full Text
##article.viewOnOriginalSite##About the authors
V. V Li
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation
Email: vera0212@yandex.ru
Department of Therapy and Family Medicine
V. S Zadionchenko
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian FederationDepartment of Therapy and Family Medicine
T. V Adasheva
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian FederationDepartment of Therapy and Family Medicine
S. V Pavlov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian FederationDepartment of Therapy and Family Medicine
N. B Shakhrai
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian FederationDepartment of Therapy and Family Medicine
References
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011). www.goldcopd.com
- Fabbri L.M., Luppi F, Beghe B, Rabe K.F. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204–12.
- Kriegsman D.M., Deeg D.J., Stalman W.A. Comorbidity of somatic chronic diseases and decline in physical functioning: the Longitudinal Aging Study Amsterdam. J Clin Epidemiol 2004; 57: 55–65.
- McGarvey L.P., John M, Anderson J.A. et al. Ascertainment of cause - specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411–5.
- Anthonisen N.R., Connett J.E., Enright P.L. et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–9.
- Holguin F, Folch E, Redd S.C. et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005–11.
- Sidney S, Sorel M, Quesenberry C.P. et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–75.
- Selvaraj C.L., Gurm H.S., Gupta R. et al. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 2005; 96: 756–9.
- Han M.K., Agusti A, Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182 (5): 598–604.
- Авдеев C.Н. Фенотипы хронической обструктивной болезни легких: особенности терапии. Пульмонология. Cons. Med. 2010; с. 3–29.
- Burgel P.R., Paillasseur J.L., Caillaud D et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531–9.
- Enriquez J.R., Parikh S.V., Selzer F. et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Chest 2011; 1403: 604–10.
- Paul Man S.F., Leipsic J.A., Man J.P., Sin D.D. Is Atherosclerotic Heart Disease in COPD a Distinct Phenotype. Chest 2011; 40 (3): 569–71.
- Мухарлямов Н.М., Саттбеков Ж.С., Сучков В.В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких. Кардиология. 1974; 12 (34): 55–61.
- Ольбинская Л.И., Белов А.А., Опаленов Ф.В. Суточный профиль артериального давления при хронических обструктивных заболеваниях легких и при их сочетании с артериальной гипертензией. Рос. кардиол. журн. 2000; 2: 20–5.
- Echave J.M., Martin-Escudero J.C., Anton E. et al. Comorbidity in COPD in Spain. Am J Respir Crit Care Med 2009; 179: A1462.
- Boutin-Forzano S, Moreau D, Kalaboka S et al. Reported prevalence and comorbidity of asthma, chronic bronchitis and emphysema: a pan-European estimation. Int J Tuberc Lung Dis 2007; 11: 695–702.
- Mannino D.M., Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32 (4): 962–9.
- Сrisafulli E, Gorgone P, Vagaggini B et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J 2010; 36: 1042–8.
- Nussbaumer-Ochsner Y, Rabe K.F. Systemic Manifestations of COPD Chest 2011;139 (1): 165–73.
- Cachofeiro V, Miana M et al. Inflammation: A Link Between Hypertension and Atherosclerosis. Current Hypertension Reviews 2009; 5 (1): 40–8.
- Gordon C, Gudi K, Krause A et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med 2011; 184: 224–32.
Supplementary files
